The GLP-1 Revolution: A New Economic Landscape
The widespread adoption of GLP-1 (Glucagon-like peptide-1) weight-loss drugs is poised to fundamentally reshape consumer behavior and industries worldwide, according to RPG Group Chairman Harsh Goenka. In a recent statement, Goenka highlighted that this shift would create distinct "winners" and "losers" across various economic sectors, urging companies to rethink their products, pricing, and customer engagement strategies.
Goenka emphasized that the "weight-loss economy" could become one of the most significant consumer shifts of our time, impacting everything from the food we eat to how we travel and what we wear.
Expected Winners in the New Economy
Several industries are projected to thrive amid the growing demand for GLP-1 medications:
- Pharmaceuticals: Manufacturers and innovators of GLP-1 drugs stand to gain substantially from increased prescriptions and research.
- Healthcare: Obesity clinics, diagnostic services, and metabolic health providers will see greater demand for specialized treatments and support.
- Fitness: Businesses offering personalized training programs and comprehensive wellness services are likely to attract more clients seeking to complement their weight-loss journey.
- Apparel: The fashion industry may experience a shift in demand towards smaller clothing sizes as average consumer weights potentially decrease.
- Travel & Aviation: Airlines could see an unexpected benefit from reduced average passenger weight, potentially leading to lower fuel consumption and operational costs.
Industries Facing Disruption
Conversely, other sectors may face significant challenges as consumer habits evolve:
- Packaged Foods: Companies specializing in snacks, confectionery, and calorie-dense products may see declining sales as consumers opt for healthier choices.
- Restaurants: Fast-food chains and establishments known for large portions could experience weaker demand as appetites and dietary preferences change.
- Alcohol: Producers of beer and spirits might observe shifts in consumption patterns, impacting sales volumes.
- Grocery Retail: Supermarkets could see fewer purchases of sugary drinks and impulse-buy items as consumers become more health-conscious.
- Food Delivery: Platforms relying heavily on indulgent meal orders may need to adapt to a demand for lighter, healthier options.
Global Impact and Growing Adoption
The shift is already evident globally. A July 2026 Gallup survey revealed that 11% of American adults reported currently taking GLP-1 medications for weight loss, a substantial increase from just 3% in 2024. In India, an estimated 2.75 lakh patients were using GLP-1 medicines by July 2026, with projections suggesting this number could reach 66 lakh by FY2031-32, according to a Kotak Institutional Equities report.
GLP-1 medications, including popular brands like Ozempic, Wegovy, Mounjaro, and Zepbound, work by mimicking or acting on hormones that regulate appetite and blood sugar. They are prescribed for conditions such as type 2 diabetes and obesity, depending on their approved indications.